14 Leading Angel Investors for Pharmaceuticals
To help you secure funding for your pharmaceutical startup, we've identified 14 active angel investors who could be the right partners for your company.
Rho Editorial Team
Angel investor funding in pharmaceuticals can provide your startup with the early capital needed to advance research, move through regulatory processes, and attract future investment.
The sector sees support from individual backers, with Paul Walker, Ryan Harris, Anders Hove, and Ryan McDonald being examples of angel investors who have funded businesses in the pharmaceutical space.
If you are raising or have just closed a round, Rho offers a platform to manage your funds with FDIC-insured accounts, corporate cards that provide up to 2% cashback, automated bill pay, spend controls, and real-time accounting integrations.
For founders in the pharmaceutical and biotech sectors, finding the right early-stage capital is a crucial first step. Knowing which angel investors are active in your field can simplify your search for funding.
Angel investors typically invest their own personal funds and can offer valuable mentorship, often moving faster than larger venture capital firms. This can be a major advantage for new companies.
To help with your fundraising, we've put together this guide on some of the top angel investors for pharma and biotech startups. It’s designed to give you a quick overview of individuals who could be a great fit for your company.
Just raised or about to? Set up your financial stack with Rho in minutes. Rho provides business banking, corporate cards, accounting integrations and more—built for startup teams moving fast.
Top Pharmaceuticals Angel Investors By Stage
Angel investors in the pharma sector typically invest during the pre-seed and seed stages. They get involved early to offer both funding and mentorship when it's most critical.
By understanding which investors operate at your stage, you can make your search for capital much more direct and efficient.
Pre-seed Angel Investors in Pharmaceuticals
Pre-seed funding is the earliest capital a startup raises, often used to validate an idea before a formal product exists. While the investors on our list typically engage at the seed stage or later, this initial capital often comes from the founders themselves or very early-stage specialists.
Seed Stage Angel Investors in Pharmaceuticals
Seed funding helps a company with product development, market research, and building out its founding team. For pharma startups at this stage, investors like Vijay Pande, Tim Shannon, and Brian Baynes are known to be active.
Series A Angel Investors in Pharmaceuticals
Series A funding is for companies that have demonstrated traction and are ready to scale their operations and user base. Some notable investors in the pharmaceutical space at this stage include Nimish Shah, Ali Behbahani, and Ed Mathers.
Series B Angel Investors in Pharmaceuticals
This round is focused on expanding market reach and taking the business to the next level against competitors. You might consider approaching investors such as Paul Walker, Ryan Harris, and Robert Garland when raising your Series B.
It's also worth noting that many investors participate in rounds across the startup lifecycle, especially those at multi-stage firms.
To help you identify the right partners, we've compiled information on leading angel investors in pharmaceuticals. You'll find details on their investment stages, preferred sectors, location, and what makes them a strong potential fit for your company.
1. Paul Walker
Paul Walker is a partner at New Enterprise Associates (NEA), a major venture capital firm. He concentrates on investments within the biopharmaceutical industry.
He typically engages in Series A and B rounds, with investments ranging from $2 million to $50 million. His portfolio includes companies like Allakos and Geron, indicating a focus on businesses with strong potential for long-term growth.
Founders of pharma or biotech companies looking for Series A or B funding may find him to be a good match. He is well-suited for teams that can benefit from the resources and network of a large venture firm.
- Investment stages: Series A, Series B
- Industries of focus: BioTech, Pharmaceuticals, Health IT, Health & Hospital Services
- Geographical presence: Based in Menlo Park, California
- Ideal investment range: $2.0M - $50.0M
- Notable portfolio companies: Allakos, Geron, Xenon Pharmaceuticals
You can find more information about Paul Walker on his firm profile and Crunchbase.
2. Ryan Harris
Ryan Harris is a General Partner at Norwest Venture Partners where he concentrates on investments across the healthcare sector. His work spans pharmaceuticals, health IT, and consumer health companies.
With a background as a medical doctor and researcher, he brings deep clinical and policy knowledge to his investment decisions. He invests from seed to Series B, with portfolio companies including Crossover Health and Onsite Dental.
Founders whose businesses have a strong clinical or health services component may find his expertise especially relevant. He is a good fit for teams looking for a partner with operational experience in the healthcare system.
- Investment stages: Seed, Series B
- Industries of focus: Pharmaceuticals, Health & Hospital Services, Health IT, Consumer Health
- Geographical presence: Based in San Francisco, California
- Ideal investment range: $1.0M - $30.0M
- Notable portfolio companies: Crossover Health, Onsite Dental
You can find more information about Ryan Harris on his firm profile and LinkedIn.
3. Anders Hove
Anders Hove is a Managing General Partner at Acorn Bioventures, where he invests in biotech, medical devices, and pharmaceutical companies. His background includes roles at the venture capital firm Venrock and the pharmaceutical giant Novartis.
With degrees in medicine and biotechnology, Hove brings a distinct clinical and scientific perspective to his investments. He tends to invest from the seed stage through Series B, and his portfolio includes companies like Anacor Pharmaceutical and Edge Therapeutics.
Founders with a strong scientific or medical foundation for their business may find Hove to be a particularly good partner. His experience suggests an appreciation for companies built on deep research and a clear clinical pathway.
- Investment stages: Seed, Series A, Series B
- Industries of focus: BioTech, Medical Devices, Pharmaceuticals
- Geographical presence: Based in New York, New York
- Ideal investment range: $100K - $5.0M
- Notable portfolio companies: Intuity Medical, Edge Therapeutics, Anacor Pharmaceutical
You can find more information about Anders Hove on his firm's website and LinkedIn.
4. Ryan McDonald
Ryan McDonald is a partner at Norwest Venture Partners, where he invests in healthcare companies. He is active from the seed stage through Series B, participating in rounds for businesses at different points in their growth.
His investment interests include pharmaceuticals, health IT, and consumer health. His portfolio, which includes companies like Scratch and Onsite Dental, shows an interest in businesses that serve both consumers and other enterprises.
Founders working on health tech or consumer health platforms may find him to be a good fit. His position at Norwest suggests he can provide access to a broad network and substantial resources for scaling companies.
- Investment stages: Seed, Series B
- Industries of focus: Pharmaceuticals, Health & Hospital Services, Health IT, Consumer Health
- Geographical presence: Based in San Francisco, California
- Ideal investment range: $1.0M - $30.0M
- Notable portfolio companies: Scratch, Onsite Dental
You can find more information about Ryan McDonald on his firm profile and LinkedIn.
5. Vijay Pande
Vijay Pande is a General Partner at Andreessen Horowitz (a16z), where he leads investments in companies at the intersection of biology and computer science. He is known for backing businesses that apply computational methods to solve complex health challenges.
His background as a Stanford professor and founder of the Folding@home project signals a deep appreciation for research-driven startups. He invests from seed to Series B, with portfolio companies like BioAge Labs and Genesis Therapeutic, highlighting his interest in longevity and drug discovery.
Founders with deep scientific or technical expertise, especially in computational biology, may find Pande to be an ideal partner. He is well-suited for teams looking for an investor who understands the technical side of building a biotech or health tech company.
- Investment stages: Seed, Series A, Series B
- Industries of focus: BioTech, Pharmaceuticals, Digital Health, Health IT
- Geographical presence: Based in San Francisco, California
- Ideal investment range: $100K - $10.0M
- Notable portfolio companies: BioAge Labs, Genesis Therapeutic, Devoted Health
You can find more information about Vijay Pande on his firm profile and LinkedIn.
6. Nimish Shah
Nimish Shah is a partner at the venture capital firm Venrock, where he concentrates on investments in the life sciences. He is active in the biotech, medical device, and pharmaceutical sectors.
He typically invests in Seed and Series A rounds, with an investment range between $3 million and $10 million. His involvement in companies like Metsera shows his participation in businesses attracting significant capital.
Founders of early-stage life science companies seeking a substantial lead investor may find him to be a strong partner. His position at Venrock provides access to a deep network and extensive resources for company building.
- Investment stages: Seed, Series A
- Industries of focus: BioTech, Medical Devices, Pharmaceuticals
- Geographical presence: Based in New York, New York
- Ideal investment range: $3.0M - $10.0M
- Notable portfolio companies: Metsera
You can find more information about Nimish Shah on his firm profile and LinkedIn.
7. Tim Shannon
Tim Shannon is a General Partner at the venture firm Canaan, where he invests in early-stage biopharmaceutical companies. With a background as a physician, he brings a clinical perspective to his work in therapeutic investments.
He concentrates on Seed and Series A rounds, backing companies with strong scientific platforms that are developing novel therapies. His portfolio includes notable companies like Arvinas, Rallybio, and IDEAYA Biosciences, which have all raised significant capital.
Founders of early-stage biotech or pharma companies could find him to be a valuable partner, particularly those who would benefit from an investor with clinical expertise. His track record indicates he is a good match for teams with ambitious long-term growth plans.
- Investment stages: Seed, Series A
- Industries of focus: BioTech, Pharmaceuticals, Health IT, Health & Hospital Services
- Geographical presence: Based in Westport, Connecticut
- Ideal investment range: $250K - $20.0M
- Notable portfolio companies: Arvinas, Rallybio, IDEAYA Biosciences
You can find more information about Tim Shannon on his firm profile and LinkedIn.
8. Ali Behbahani
Ali Behbahani is a General Partner at New Enterprise Associates (NEA), where he invests in biopharmaceuticals, medical devices, and specialty pharma companies. With a medical degree, he brings a clinical viewpoint to his investment work.
He is active in Series A and B rounds, often participating in substantial fundraises for companies like Amber Therapeutics and Monte Rosa Therapeutics. This indicates a focus on businesses with high-growth potential that require significant capital.
Founders of biopharma or medical device companies seeking a large, experienced partner for their Series A or B rounds may find him to be a good fit. His role at NEA provides portfolio companies with access to a broad network and extensive resources.
- Investment stages: Series A, Series B
- Industries of focus: BioTech, Pharmaceuticals, Medical Devices, Health & Hospital Services, Health IT
- Geographical presence: Based in Philadelphia, Pennsylvania
- Ideal investment range: $2.0M - $50.0M
- Notable portfolio companies: Monte Rosa Therapeutics, Amber Therapeutics, 858 Therapeutics
You can find more information about Ali Behbahani on his firm profile and LinkedIn.
9. Robert Garland
Robert Garland is a partner at New Enterprise Associates (NEA), a major venture capital firm. He concentrates on investments in the medical device and pharmaceutical industries.
He is active from the seed stage through Series B, with a history of participating in significant funding rounds for companies like Sagimet Biosciences and Trevena. This indicates an interest in businesses with high-growth potential that require substantial capital for development.
Founders of life science companies, particularly in medical devices or pharma, may find him to be a good partner. He is well-suited for teams seeking a significant investor for their Series A or B rounds who can bring the resources of a large firm.
- Investment stages: Seed, Series A, Series B
- Industries of focus: Medical Devices, Pharmaceuticals
- Geographical presence: Based in San Francisco, California
- Ideal investment range: $2.0M - $50.0M
- Notable portfolio companies: Sagimet Biosciences, Trevena, Cleave Therapeutics
You can find more information about Robert Garland on his firm's website and LinkedIn.
10. Colin Bryant
Colin Bryant is a partner at New Enterprise Associates (NEA), a large venture capital firm. He invests in enterprise, consumer internet, and pharmaceutical companies.
He participates in Series A and B rounds, with investments that can range up to $50 million. His portfolio includes companies like Stability AI and Sitetracker, showing an interest in technology-driven businesses that require significant capital for growth.
Founders of companies in the enterprise and consumer tech sectors looking for a substantial Series A or B partner may find him to be a good fit. His role at NEA means he can provide portfolio companies with access to a wide network and considerable resources.
- Investment stages: Series A, Series B
- Industries of focus: Enterprise, Pharmaceuticals, Consumer Internet
- Geographical presence: Based in San Francisco, California
- Ideal investment range: $2.0M - $50.0M
- Notable portfolio companies: Stability AI, Sitetracker, Metromile
You can find more information about Colin Bryant on his firm profile and LinkedIn.
11. Brian Baynes
Brian Baynes is an investor and serial founder associated with Pillar VC and Petri. He has a history of building and leading companies, particularly in the biotech and life sciences sectors.
With a PhD from MIT and experience founding multiple companies, he brings deep technical and operational knowledge to his investments. He tends to focus on Seed and Series A rounds for companies in the biotech and pharmaceutical industries.
Founders with a strong scientific or engineering foundation for their business may find him to be a great fit. He is well-positioned to support teams that can benefit from his experience in building companies from the ground up.
- Investment stages: Seed, Series A
- Industries of focus: BioTech, Pharmaceuticals, Digital Health, Health IT, Health & Hospital Services
- Geographical presence: Based in Boston, Massachusetts
- Ideal investment range: $250K - $500K
- Notable portfolio companies: Joule Unlimited Technologies
You can find more information about Brian Baynes on his firm profile and LinkedIn.
12. Blake Wu
Blake Wu is a member of the healthcare team at New Enterprise Associates (NEA), a prominent venture capital firm. He is involved in investments across the healthcare spectrum, including biotech and pharmaceuticals.
His background in equity research and private equity provides a strong financial lens for his investment decisions. He is active in Series A and B rounds, with portfolio companies like Xenon Pharmaceuticals and AVEO Oncology showing his involvement with later-stage and public companies.
Founders of health IT, biotech, or pharmaceutical companies looking for a Series A or B partner may find him to be a good fit. He is well-suited for teams that can benefit from the resources of a large firm and an investor with deep financial expertise.
- Investment stages: Series A, Series B
- Industries of focus: BioTech, Pharmaceuticals, Health IT, Health & Hospital Services
- Geographical presence: Based in Menlo Park, California
- Ideal investment range: $2.0M - $50.0M
- Notable portfolio companies: Xenon Pharmaceuticals, AVEO Oncology, Slope.io
You can find more information about Blake Wu on his firm profile and LinkedIn.
13. Ed Mathers
Ed Mathers is a partner at New Enterprise Associates (NEA), where he focuses on biopharmaceutical investments. He is primarily active in Series A and Series B rounds, bringing the resources of a major venture firm to his portfolio companies.
A key aspect of his investment approach is his participation in substantial funding rounds for companies with high-growth potential. His involvement with businesses like Cardurion Pharmaceuticals and MBX Biosciences shows a focus on backing teams that require significant capital for development and scaling.
Founders of biotech or pharma companies seeking a lead investor for their Series A or B rounds may find him to be a good match. He is well-suited for teams that can benefit from the deep network and company-building experience of a large firm like NEA.
- Investment stages: Series A, Series B
- Industries of focus: BioTech, Pharmaceuticals, Health IT, Health & Hospital Services
- Geographical presence: Based in Maryland
- Ideal investment range: $2.0M - $50.0M
- Notable portfolio companies: Cardurion Pharmaceuticals, MBX Biosciences, Inversago Pharma
You can find more information about Ed Mathers on his firm profile and LinkedIn.
14. Rob Ness
Rob Ness is a General Partner at Asymmetry Ventures, bringing a diverse background that includes military service and management consulting to his role. He invests across a wide range of industries, from tech to life sciences.
His investment focus is notably broad, covering sectors like AI, biotech, and real estate, with a preference for Seed and Series A rounds. His investment in the AI company Mycroft highlights an interest in technology-driven businesses.
Founders with early-stage companies in his areas of interest may find him to be a good fit. His experience in economics and consulting suggests he is a good partner for teams with a clear business model and growth strategy.
- Investment stages: Seed, Series A
- Industries of focus: Material Science, Health & Hospital Services, Real Estate/PropTech, Medical Devices, SaaS, Enterprise, BioTech, Pharmaceuticals, AI, IoT
- Geographical presence: Based in the San Francisco Bay Area
- Ideal investment range: $125K - $500K
- Notable portfolio companies: Mycroft
You can find more information about Rob Ness on his firm's website and LinkedIn.
What Startup Founders Should Look for in a Pharmaceuticals Investor
When looking for a pharmaceutical investor, it's about finding a partner, not just a check. As our list shows, many investors in this space bring more than capital, often offering deep scientific or clinical backgrounds that can be invaluable for research-driven startups.
To find the right fit for your company, consider these key points:
- Expertise Alignment: Look for an investor with a background in your specific area, whether it's pure pharma, biotech, or medical devices.
- Network and Resources: Many investors on this list are partners at large firms, giving you access to a broad network for hiring, partnerships, and future funding rounds.
- Geographic and Stage Focus: Note the concentration in hubs like Boston and the Bay Area, and ensure their typical investment stage matches yours.
Taking the time to research these aspects can help you build a targeted list and make your fundraising process more effective.
Raise Confidently with Rho
Fundraising requires significant time and energy, so a focused list of relevant investors is a major asset. It allows you to direct your efforts where they will have the most impact.
After a successful fundraise, managing that capital efficiently is your next priority. If you’ve just raised, Rho can help you set up your financial stack in minutes with our integrated business banking, corporate cards, and bill pay solutions.
With our platform handling your finances, you can be confident your angel capital is directed toward growth and operations. This frees you from manual admin and lets you focus on building your company.
FAQs about Pharmaceuticals Angel Investors
How do I find pharma angel investors outside major hubs?
Look into local university research parks, industry-specific conferences, and online platforms. A methodical approach to finding angel investors can uncover opportunities beyond traditional venture capital centers.
Do pharma angel investors also fund digital health startups?
Yes, many investors in this space are also active in digital health, especially where it intersects with biotech or patient care. Their interest often extends to health IT and computational biology, reflecting a broader view of healthcare innovation.
What is the typical check size for a pharma angel investor?
It varies widely. Early-stage checks can be from $25k to $100k, while partners at VC firms acting as angels or leading seed rounds can invest significantly more, sometimes in the millions.
Are there angel investors for later-stage pharma companies?
While angels are most common early on, some do participate in later stages like Series C. This often happens when they follow on from a previous investment or join a syndicate with strong conviction.
How important is intellectual property to pharma investors?
A strong IP position is critical for biotech companies. Investors need to see that your discoveries are protected through patents or have a clear path to patentability, as this forms the core value of the business.
How can Rho help after I secure angel funding?
Once you've raised capital, our platform helps you manage it effectively. Rho offers integrated banking, corporate cards, and expense management, so you can focus on growing your company instead of financial admin.